Waters Corporation (WAT) Q2 2025 Earnings Call Transcript

Waters Corporation reported strong Q2 2025 results, with sales up 8% constant currency and non-GAAP EPS up 12%, exceeding guidance due to robust pharma growth, strong LC/MS instrument sales, and effective commercial execution, despite weakness in the TA division. Consequently, the company raised its full-year 2025 sales and non-GAAP EPS guidance. Management provided extensive detail on the pending acquisition of BD's Biosciences and Diagnostic Solutions business, reiterating confidence in achieving a 7% revenue CAGR and mid-teens adjusted EPS CAGR for the combined entity by 2030, driven by $345 million in identified synergies from operational efficiencies, commercial excellence, and expansion into high-growth adjacencies like mass spec diagnostics and bioseparations, with significant untapped opportunities in microbiology.

Analysis

Waters Corporation reported a strong second quarter for 2025, with constant currency sales growth of 8% and non-GAAP EPS growth of 12% to $2.95, surpassing the high end of its guidance. This performance was driven by the Pharma segment, which grew 11% on the back of a robust instrument replacement cycle and significant traction from new products like the Alliance iS, which saw sales increase 300% year-over-year. Recurring revenues were a key contributor, growing 11% with a notable $8 million pull-forward in chemistry sales attributed to tariff dynamics; excluding this, underlying constant currency growth was a solid 7%. This strength was partially offset by a 6% decline in the TA division, primarily due to macroeconomic headwinds impacting materials and polymer testing in the Americas. In response to the strong momentum, management raised its full-year 2025 constant currency sales growth guidance to 5.5%-7.5% and non-GAAP EPS guidance to $12.95-$13.05.

The earnings call was also heavily focused on the pending acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions business. Management presented a detailed framework for achieving a combined 7% revenue CAGR and mid-teens adjusted EPS CAGR through 2030. This is predicated on realizing $345 million in adjusted EBITDA synergies, comprising $200 million in cost savings and $290 million in revenue synergies. Key revenue drivers include applying Waters' commercial playbook to BD's assets (e.g., increasing service attachment from 40% and boosting e-commerce adoption) and leveraging cross-selling opportunities, such as introducing Waters' mass spectrometry platforms into BD's established network of specialty diagnostic labs. Critically, management highlighted significant value creation opportunities not included in their base model, including a plan to close a 180 basis point growth gap and a 700 basis point margin gap in BD's microbiology business versus its primary competitor.

Key Decisions for Investors

• Investors should view the strong Q2 results and raised full-year guidance as validation of the core business's operational strength, particularly in the high-margin pharma and recurring revenue segments.
• The detailed synergy plan for the BD acquisition, especially the $290 million in targeted revenue synergies, is the central pillar of the deal's long-term value proposition and warrants close scrutiny of execution post-close.
• It is prudent to monitor the persistent weakness in the macro-sensitive TA division and management's conservative assumptions for China, as these factors could pose headwinds to achieving the high end of the new guidance range.
• Consider the potential for upside not priced into the current deal model, specifically from the planned operational turnaround of BD's microbiology unit and the entry into new markets like mass spectrometry for microbial identification, which represent significant long-term catalysts.